In 2010, Johnson & Johnson initiated one of the largest medical device recalls in history when it recalled its DePuy ASR hip implants used in over 93,000 patients.
By now, most people have seen one of the many TV commercials advising those women who suffered blood clots after taking Yaz or Yasmin that they may qualify for compensation. The good news is, this is true for many patients.
For over a year, DrugRisk has tracked safety concerns over the popular anticoagulant drug Pradaxa. Numerous health agencies have warned that the medication can cause internal bleeding problems at a greater rate than traditional blood thinners like warfarin.
DrugRisk has learned of a new development in the NuvaRing blood clot litigation that could mean a settlement for victims in the near future. A judge overseeing lawsuits recently delayed the start of the first trial and asked lawyers to give an updated count of cases.
DrugRisk has received troubling new information about the popular antipsychotic drug Risperdal. The manufacturer has pled guilty to falsely marketing the drug, and experts have warned that it may cause abnormal breast growth in patients, especially children and adult males.
Earlier this year, a study from the American Medical Association raised concerns with the millions of patients taking diabetes drugs like Byetta when experts warned the drugs may be linked to higher risks of pancreatic cancer.
Since it was released in 2000, the Mirena IUD from Bayer has become one of the most popular forms of birth control. Nillions of women have chosen the one-time implant that can work for up to 5 years over the hassle of taking a daily pill.
For years, DrugRisk has tracked the research, warnings and legal action relating to the birth control drugs Yaz and Yasmin, in an effort to help the thousands of women affected by blood clot injuries.
Amid increasing warnings that the popular anticoagulant drug Pradaxa may present serious internal bleeding risks, and a growing number of lawsuits from patients and families who have been affected, DrugRisk learned that the maker of the drug went to the FDA last month for help.
Merck subsidiary Organon Pharmaceuticals is facing a growing number of lawsuits from women who suffered blood clot injuries while using the NuvaRing contraceptive device.